Gilead Sciences, Inc. (GILD)
| Market Cap | 184.91B |
| Revenue (ttm) | 29.44B |
| Net Income (ttm) | 8.51B |
| Shares Out | 1.24B |
| EPS (ttm) | 6.78 |
| PE Ratio | 21.97 |
| Forward PE | 17.15 |
| Dividend | $3.28 (2.28%) |
| Ex-Dividend Date | Mar 13, 2026 |
| Volume | 11,285,202 |
| Open | 143.56 |
| Previous Close | 143.77 |
| Day's Range | 143.37 - 150.00 |
| 52-Week Range | 93.37 - 157.29 |
| Beta | 0.39 |
| Analysts | Strong Buy |
| Price Target | 143.50 (-3.66%) |
| Earnings Date | Feb 10, 2026 |
About GILD
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an inj... [Read more]
Financial Performance
In 2025, Gilead Sciences's revenue was $29.44 billion, an increase of 2.40% compared to the previous year's $28.75 billion. Earnings were $8.51 billion, an increase of 1672.92%.
Financial StatementsAnalyst Forecast
According to 18 analysts, the average rating for GILD stock is "Strong Buy." The 12-month stock price target is $143.5, which is a decrease of -3.66% from the latest price.
News
10 Best CEFs This Month: Average Yield Of 9.7% (February 2026)
The article presents a rigorously screened list of 10 top closed-end funds, or CEFs, for income investors, offering an average 9.7% yield and -10% NAV discount. Selections emphasize sector diversifica...
Johanna Mercier on Gilead's HIV prevention innovation
Johanna Mercier, Chief Commercial & Corporate Affairs Officer at Gilead Sciences, discusses Gilead's groundbreaking HIV prevention innovation — a twice-yearly injection with 99.9% efficacy during this...
Gilead's experimental HIV treatment shows low discontinuation rates in studies
Gilead Sciences on Wednesday said its experimental single-tablet HIV treatment was generally well tolerated with low discontinuation rates, positioning the single-tablet regimen as a potential option ...
Gilead's Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #CROI2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of new Phase 3 ARTISTRY-1 and ARTISTRY-2 trial data at CROI 2026 showing a treat...
Gilead Sciences to Present at Upcoming Investor Conferences
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: TD Cowen Annual Health Ca...
Why is Arcellx stock up 80% today? Gilead's $7.8B answer
Arcellx stock (NASDAQ: ACLX) climbed roughly 80% in premarket trade on Monday after Gilead Sciences agreed to buy the cancer-therapy developer in a $7.8 billion all-cash deal. The stock's move wasn't ...
Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion
Gilead Sciences will pay as much as $7.8 billion to acquire its partner Arcellex in its largest deal since 2020, the biopharma company said on Monday, as it looks to strengthen its lineup of cancer tr...
Gilead shows its belief in its partner's cancer treatment with a $7.8 billion buyout
Shares of Arcellx shot up toward a fresh record in early Monday trading, after Gilead Sciences agreed to buy the rest of the shares it doesn't already own of the biotechnology company, in a deal with ...
Gilead Sciences to Buy Arcellx in Deal Valued at $7.8 Billion
Gilead Sciences has agreed to buy the rest of development partner Arcellx in a deal that values the biotechnology company at about $7.8 billion at closing.
This Biotech Stock Is Surging 80%. Gilead Sciences Has Agreed to Buy It.
Gilead Sciences is paying an 80% premium to Friday's closing price.
Gilead to acquire Arcellx for $7.8 billion
Gilead Sciences said on Monday it will buy cancer therapy developer Arcellx for an implied equity value of $7.8 billion, sending shares of Arcellx climbing 77.8% to $113.99 in premarket trading.
Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel
FOSTER CITY, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a definitive agreement to acquire Arcellx (Nasdaq: ACLX) for ...
Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel
FOSTER CITY, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)-- #ACLX--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a definitive agreement to acquire Arcellx (Nasdaq: AC...
Time To Take Profits On Gilead Sciences (Rating Downgrade)
Gilead Sciences, Inc. shares have risen more than 43% over the past year. I continue to believe that its three key drugs remain Biktarvy, Yeztugo, and Livdelzi, whose total sales grew 10.8% year-over-...
Gilead to Present New HIV Treatment and Prevention Data at CROI 2026, With a Focus on Expanding Options
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #CROI2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced details of new clinical and real-world data from its innovative HIV treatment and prevention port...
Gilead Analysts Boost Their Forecasts After Upbeat Q4 Earnings
Gilead Sciences Inc. (NASDAQ: GILD) posted upbeat fourth-quarter earnings but issued weak fiscal 2026 guidance on Tuesday.
Gilead Sciences, Inc. (GILD) Q4 2025 Earnings Call Transcript
Gilead Sciences, Inc. (GILD) Q4 2025 Earnings Call Transcript
Gilead Stock Slips After Q4 Earnings, Weak FY26 Guidance
Gilead Sciences Inc. (NASDAQ: GILD) shares slipped in Tuesday's extended trading after the company released its fourth-quarter earnings report with weak fiscal 2026 guidance.
Gilead Sciences Profit Rises on Growth of Liver Disease, HIV Products
The biopharmaceutical company may start to offer two cancer therapies and an additional HIV treatment option this year.
Gilead quarterly results beat Wall Street estimates
Gilead Sciences on Tuesday reported fourth-quarter sales and profit that came in slightly above Wall Street estimates, while its 2026 financial forecast was at the lower end of analysts' expectations.
Gilead Sciences Announces 3.8 Percent Increase in First Quarter 2026 Dividend
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Dividend--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company's Board of Directors has declared an increase of 3.8% in the company's quarterly...
Gilead Sciences Announces Fourth Quarter and Full Year 2025 Financial Results
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2025. “Our fourth quarter and full...
Gilead Sciences: Buy This Stock For Both Dividend And Growth
I rate Gilead Sciences (GILD) a 'Buy' with a $191 price target. It offers an attractive 2.1% dividend yield and low volatility. GILD's revenue is anchored by Biktarvy, protected by exclusivity through...
FDA Approves Label Update for Kite's Yescarta® for Relapsed/Refractory Primary Central Nervous System Lymphoma
SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) approved an update to the Yescarta® (axicabtagene ciloleucel) ...
Gilead Sciences to Release Fourth Quarter & Full Year 2025 Financial Results on Tuesday, February 10, 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2025 financial results and guidance will be released on Tue...